Latest News about REGN
Recent news which mentions REGN
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
July 03, 2024
From Benzinga
From Benzinga
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
June 27, 2024
From Benzinga
3 Biotech Stocks That Could Make Your Grandchildren Rich
June 27, 2024
From InvestorPlace
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
June 24, 2024
From Benzinga
From Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
From Benzinga
From InvestorPlace
From Benzinga
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
June 13, 2024
From Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
From Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
June 07, 2024
From Motley Fool
What's Going On With FibroGen Stock Tuesday?
June 04, 2024
From Benzinga
3 Stocks to Watch in Active Growth ETF FDG
June 04, 2024
From ETF Trends
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
June 04, 2024
From Benzinga
From Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
June 03, 2024
From Benzinga
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31, 2024
From Benzinga
What's Going On With Biohaven Stock Wednesday?
May 29, 2024
From Benzinga
2 Biotech Stocks to Buy in May
May 25, 2024
From Motley Fool
From Benzinga
From Motley Fool
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.